Evaluation of Serum Levels of Chemokines during Interferon-β Treatment in Multiple Sclerosis Patients: A 1-Year, Observational Cohort Study

Author： Comini-Frota Elizabeth R.  

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.25, Iss.11, 2011-11, pp. : 971-981

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon-β1b for the treatment of multiple sclerosis

By Lam Sum   Wang Shan   Gottesman Malcolm  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 8, 2008-08 ,pp. : 1111-1117

Informa Healthcare

Access to resources Recommend Favorite

Interferon-β1b in the treatment of multiple sclerosis

By Río Jordi   Montalban Xavier  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2877-2886

Informa Healthcare

Access to resources Recommend Favorite

Subcutaneous Recombinant Interferon-β-1a (Rebif®): A Review of its Use in the Treatment of Relapsing Multiple Sclerosis

By Sanford Mark   Lyseng-Williamson Katherine A.  

Drugs, Vol. 71, Iss. 14, 2011-10 ,pp. : 1865-1891

Adis International

Access to resources Recommend Favorite

Improving Compliance with Interferon-β Therapy in Patients with Multiple Sclerosis

By Portaccio Emilio   >  

CNS Drugs, Vol. 23, Iss. 6, 2009-05 ,pp. : 453-462

Adis International

Access to resources Recommend Favorite

Interferon-β-1b: A Review of its Use in Multiple Sclerosis

By Plosker Greg L.  

CNS Drugs, Vol. 25, Iss. 1, 2011-01 ,pp. : 67-88

Adis International

Access to resources Recommend Favorite